Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PPM1B | O75688 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5213078 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL172658 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL132806 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL5216014 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL6784103 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL5220519 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL1931445 | 0.86 | ESR2 (0.43) | NPC1ALDH1A1RAB9A | |
| SCHEMBL5426977 | 0.82 | CHRNB2 (0.44) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL5426986 | 0.82 | CHRNB2 (0.44) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL5426982 | 0.82 | CHRNB2 (0.44) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037975-A1 | Substituted-1,3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | BELLEAU BERNARD | 2007-02-15 | — | — | US | claimed |
| US-20040254201-A1 | Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties | BELLEAU BERNARD (CA) | 2004-12-16 | — | — | US | claimed |
| US-20030087918-A1 | Synthesis of substituted 1,3-dioxolanes and substituted 1,3-oxathiolanes with antiviral properties | BIOCHEM PHARMA INC. (CA) | 2003-05-08 | — | — | US | claimed |
| EP-1467990-B1 | PROCESS FOR PRODUCING DIOXOLANE NUCLEOSIDE ANALOGUE PRECURSORS | SHIRE BIOCHEM INC (CA) | 2012-03-07 | — | — | EP | disclosed |
| EP-1467990-B1 | PROCESS FOR PRODUCING DIOXOLANE NUCLEOSIDE ANALOGUE PRECURSORS | SHIRE BIOCHEM INC (CA) | 2012-03-07 | — | — | EP | disclosed |
| US-8076347-B2 | (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine (OddC); \"L\"-nucleoside that exhibits anti-tumor activity; anticarcinogenic agent for non-small cell lung cancer, colon, breast, prostate, ovarian, CNS, renal, and lymphoma cancer, leukemia, melanoma | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076347-B2 | (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine (OddC); \"L\"-nucleoside that exhibits anti-tumor activity; anticarcinogenic agent for non-small cell lung cancer, colon, breast, prostate, ovarian, CNS, renal, and lymphoma cancer, leukemia, melanoma | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-7560550-B2 | Method for the production of OH protected[4-(2.6-diamino-9H-purine-9-yl)-1.3-dioxolane-2-yl]methanol derivatives | RFS PHARMA, LLC (US) | 2009-07-14 | — | — | US | disclosed |
| US-7442813-B2 | Process for producing dioxolane nucleoside analogues | SHIRE BIOCHEM INC. (CA) | 2008-10-28 | — | — | US | disclosed |
| US-7442813-B2 | Process for producing dioxolane nucleoside analogues | SHIRE BIOCHEM INC. (CA) | 2008-10-28 | — | — | US | disclosed |
| US-20080171758-A1 | Compounds and methods for the treatment of cancer | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC (US) | 2008-07-17 | — | — | US | disclosed |
| US-20030187262-A1 | Stereoselective synthesis of nucleoside analogues | BIOCHEM PHARMA INC. (CA) | 2003-10-02 | — | — | US | disclosed |
| WO-2003062229-A1 | PROCESS FOR PRODUCING DIOXOLANE NUCLEOSIDE ANALOGUES | SHIRE BIOCHEM INC. (CA) | 2003-07-31 | — | — | WO | disclosed |
| US-20030087918-A1 | Synthesis of substituted 1,3-dioxolanes and substituted 1,3-oxathiolanes with antiviral properties | BIOCHEM PHARMA INC. (CA) | 2003-05-08 | — | — | US | disclosed |
| US-6541625-B2 | Stereoselectively hydrolyzing an anomeric mixture of 2-benzoyloxydioxolanecarboxylate with an enzyme; separating product; replacing carboxylate by reaction with a purine or pyrimidinyl derivative | BIOCHEM PHARMA, INC. (CA) | 2003-04-01 | — | — | US | disclosed |
| US-20030013660-A1 | Dioxolane analogs for improved inter-cellular delivery | SHIRE BIOCHEM INC. (CA) | 2003-01-16 | — | — | US | disclosed |
| US-6350753-B1 | 2-ACETOXYMETHYL-4-(THYMIN-1'-YL)-1,3,-DIOXOLANE; 2-BENZOYLOXYMETHYL-4-(CYTOSIN-1'-YL)-1,3-DIOXOLANE; ANTIVIRAL AGENTS, PARTICULARY FOR THE TREATMENT OF THE HIV INFECTIONS IN MAMMALS, ESPECIALLY HUMANS | BIOCHEM PHARMA INC. (CA) | 2002-02-26 | — | — | US | disclosed |
| US-20020006635-A1 | Stereoselective synthesis of nucleoside analogues | BIOCHEM PHARMA, INC. (CA) | 2002-01-17 | — | — | US | disclosed |
| EP-0956021-A1 | L-$g(b)-DIOXOLANE URIDINE ANALOGS AND METHODS FOR TREATING AND PREVENTING VIRUS INFECTIONS | YALE UNIVERSITY (US) | 1999-11-17 | — | — | EP | disclosed |
| WO-1998020879-A1 | L-β-DIOXOLANE URIDINE ANALOGS AND METHODS FOR TREATING AND PREVENTING VIRUS INFECTIONS | YALE UNIVERSITY (US) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187262-A1 | Stereoselective synthesis of nucleoside analogues | PNP, CTRC, CPN1 | CHRNB2 1905/4885CHRNA5 1249/4885CHRNA7 1907/4885 |
| US-20070037975-A1 | Substituted-1,3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | IFNAR1, MAVS, IFNG | CHRNB2 4699/4885CHRNA5 4345/4885CHRNA7 4166/4885 |
| US-20030013660-A1 | Dioxolane analogs for improved inter-cellular delivery | SLC19A1, SLC29A1, SLC29A2 | CHRNB2 2452/4885CHRNA5 3369/4885CHRNA7 3606/4885 |
| US-20030087918-A1 | Synthesis of substituted 1,3-dioxolanes and substituted 1,3-oxathiolanes with antiviral properties | IFNAR1, ZC3HAV1, NUDT1 | CHRNB2 4678/4885CHRNA5 4378/4885CHRNA7 4035/4885 |
| US-20040254201-A1 | Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties | IFNAR1, ZC3HAV1, MAVS | CHRNB2 4555/4885CHRNA5 4167/4885CHRNA7 3788/4885 |
| US-20080171758-A1 | Compounds and methods for the treatment of cancer | DCTD, DCK, DUT | CHRNB2 3314/4885CHRNA5 3618/4885CHRNA7 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.